ALBAN研究:阿替利珠单抗联合BCG治疗高危NMIBC的III期试验
ALBAN是一项国际、随机、开放标签III期试验,在BCG初治高危NMIBC患者中比较阿替利珠单抗联合BCG与单用BCG的疗效。联合组治疗相关不良事件及≥3级不良事件发生率高于单用BCG组。
要点
- 阿替利珠单抗联合BCG未改善高危NMIBC患者的EFS。
- 联合组治疗相关不良事件及≥3级不良事件发生率更高。
- PD-(L)1联合BCG的疗效可能因具体药物和情境而异。
核心结论
- 在BCG初治高危NMIBC患者中,阿替利珠单抗联合1年BCG治疗未显示EFS获益,与另一种PD-(L)1药物联合BCG的阳性EFS结果相反,提示检查点联合BCG的获益可能具有情境和药物特异性而非类效应。
研究设计与样本
- ALBAN(GETUG-AFU 37)为国际、1:1随机、开放标签III期试验,比较阿替利珠单抗联合BCG(B组)与单用BCG(A组)在BCG初治高危NMIBC患者中的疗效。
- 共255例随机至A组,262例至B组。
- 主要终点为研究者评估的无事件生存(EFS)。
主要发现
- 试验未达到主要终点,两组EFS无显著差异,风险比为0.98(95%CI 0.71-1.36,P=0.9106)。
- EFS结果在所有预设亚组中一致。
- 联合治疗的安全性特征与单药一致,但治疗相关不良事件(TRAEs)和≥3级TRAEs发生率高于单用BCG。
临床怎么用
- 不推荐在BCG初治高危NMIBC患者中常规联合阿替利珠单抗与BCG治疗。
- 联合治疗需关注更高的治疗相关不良事件风险。
- 未来需通过生物标志物筛选获益人群并优化检查点抑制剂与BCG联合的时机、疗程和给药途径。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Standard treatment of high-risk non-muscle-invasive bladder cancer (NMIBC) after transurethral resection of bladder tumor is intravesical instillation with Bacillus Calmette-Guérin (BCG) (induction and maintenance regimens); however, BCG therapy still fails in 30%-40% of patients. Prior studies suggest that programmed death-ligand 1 (PD-L1) expression and alterations in immune infiltration might be associated with BCG failure. PATIENTS AND METHODS: The ALBAN trial is an international, 1 : 1 randomized, open-label phase III trial comparing the combination of atezolizumab (an anti-PD-L1 antibody) and BCG (arm B) versus BCG alone (arm A) for BCG-naive patients with high-risk NMIBC. The primary endpoint was investigator-assessed event-free survival (EFS). Key secondary endpoints included high-grade recurrence-free survival, complete response rate, and duration of response in patients with carcinoma in situ disease, as well as overall survival. RESULTS: In total, 255 patients were randomly assigned to arm A and 262 to arm B. The trial did not meet its primary endpoint; there was no significant difference in EFS between arms, with a hazard ratio of 0.98 (95% confidence interval 0.71-1.36, P = 0.9106). EFS results were consistent across all prespecified subgroups. The safety profile of the treatment combination was consistent with that of the individual agents but showed higher rates of treatment-related adverse events (TRAEs) and grade ≥3 TRAEs than BCG alone. CONCLUSION: This phase III trial in BCG-naive patients with high-risk NMIBC did not demonstrate an EFS benefit from the addition of atezolizumab to 1-year BCG therapy, in contrast to positive EFS results reported with another PD-(L)1 agent, suggesting that any benefit from checkpoint-BCG therapy may be context- and agent-specific rather than a class effect. Future research should focus on biomarker-driven patient selection and optimization of the timing, duration, and route of checkpoint delivery relative to BCG.
引用
- Roupret M, Bertaut A, Pignot G, et al. ALBAN (GETUG-AFU 37): a phase III, randomized, open-label international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Guérin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC). Ann Oncol. 2025. PMID: 41110692. doi:10.1016/j.annonc.2025.09.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。